Filing Flows › Companies › Century Therapeutics › Report card
Century Therapeutics earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate4 of 4 reports beat the EPS estimate
Century Therapeutics (IPSC) beat the analysts' EPS estimate in 4 of its last 4 reports (100%), by +18.3% on average. Next report: Nov 12, 2026, analysts expect EPS −$0.11.
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | GAAP EPS |
|---|---|---|---|---|---|
| Q to Jun 2026 | Aug 12, 2026 | −$0.12 | −$0.11 | +2.5% | −$0.17 |
| Q to Mar 2026 | May 13, 2026 | −$0.17 | −$0.11 | +37.1% | −$0.11 |
| Q to Dec 2025 | Mar 12, 2026 | −$0.30 | −$0.25 | +16.7% | — |
| Q to Sep 2025 | Nov 13, 2025 | −$0.39 | −$0.32 | +16.9% | −$0.40 |
Estimates and reported EPS are the Street's adjusted figures; GAAP EPS is from the filing (SEC XBRL). No daily prices are on file for these report days, so the stock's moves are not shown.
Charts
The next report: what to expect → Century Therapeutics: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.